-
Xikang cooperates with afinita biotech to develop new anti-cancer monoclonal antibody drugs
Time of Update: 2020-04-03
Xikang will provide cell line development, process development, mass production and other professional technologies for afinita biotech anti-cancer monoclonal antibody new drugs with its plant facilities in Zhubei, Taiwan and Wuhan, China.
-
The "National Key Laboratory for antibody drug development" built by Huabei pharmaceutical new drug research and development company passed the expert acceptance organized by the Ministry of science and technology
Time of Update: 2020-04-03
On January 13, the Ministry of science and technology organized an acceptance expert group composed of nine experts in the field of drug research and development to carry out
-
Guilin Sanjin Pharmaceutical Co., Ltd. obtained approval for clinical trial on recombinant anti EGFR human mouse chimeric monoclonal antibody injection
Time of Update: 2020-04-03
Next, the company will carry out the clinical trial study of recombinant anti EGFR human mouse chimeric monoclonal antibody injection as soon as possible in accordance with the requirements of the above-mentioned drug clinical approval documents.
-
Clinical approval of recombinant human mouse chimeric anti-CD20 monoclonal antibody injection
Time of Update: 2020-04-03
According to the website of the State Food and drug administration, the approval status of the recombinant human mouse chimeric anti-CD20 monoclonal antibody injection (cxsl1100072
-
Fuhong Hanlin, a subsidiary of Fosun Pharmaceutical, obtained the first clinical approval for monoclonal antibody drugs
Time of Update: 2020-04-03
This approval is the first clinical approval of Fuhong Hanlin since its establishment, and also the first clinical approval of monoclonal antibody drugs obtained by Fosun Pharmaceutical holding member enterprises.
-
Application for clinical acceptance of recombinant anti HER2 humanized monoclonal antibody for injection in uniform pharmaceutical
Time of Update: 2020-04-03
Whether the above new drug application of Wanle pharmaceutical can pass the clinical review and obtain the approval document is uncertain, and there is great uncertainty in the approval progress and results.
-
All human monoclonal antibody injection of Watson biological recombinant anti TNF - α obtained the approval of clinical trial in Korea
Time of Update: 2020-04-03
Jiahe biopharmaceutical Co., Ltd., a subsidiary of Watson biology, has obtained the clinical trial approval document issued by the Ministry of food and drug safety of South Korea
-
Clinical approval of recombinant human anti TNF α monoclonal antibody for injection
Time of Update: 2020-04-03
Jiankangyuan and Lizhu group's joint-venture subsidiary announced today (March 7) that Zhuhai Lizhu monoclonal antibody Biotechnology Co., Ltd
(hereinafter referred
-
CITIC Guojian's "Herceptin" monoclonal antibody generic cypriotin obtained clinical approval
Time of Update: 2020-04-03
The pace of approval of mAbs is accelerating
On the morning of May 30, the State Administration of food and Drug Administration reported that the approval status
-
Haizheng pharmaceutical "recombinant human mouse chimeric anti-CD20 monoclonal antibody injection" obtained clinical approval
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA), the approval status of "recombinant human mouse chimeric anti-CD20 monoclonal antibody injection", a clinical heavyweight McAb drug declared by Haizheng pharmaceutical, has changed to "approved pending".
-
Heavyweight: 100 Xinyi provides 2019 ncov full set of antibodies - and is humanized
Time of Update: 2020-04-03
In order to achieve this method, four core materials and at least one germplasm control product are needed, i.e. antigen, gold standard detection antibody, c-line antibody and quality control positive antibody.
-
First in China, approved clinical application of Lizhu pharmaceutical's monoclonal antibody IL-17A / F
Time of Update: 2020-02-20
The recombinant anti-human IL-17A / F humanized monoclonal antibody injection can simultaneously target the homologous dimer il-17a-a and il-17f-f, as well as the heterodimer il-17a-f.
-
Essence pharmaceuticals terminates the development of two human monoclonal antibody products
Time of Update: 2020-02-20
In the evening of February 19th, the essence pharmaceutical announced that it signed the cooperation and authorization agreement with Kadmon Corporation and LLC in October 29, 2015
-
Team of Sun Yat sen University: SARS virus antibody can exist for a long time
Time of Update: 2020-02-18
Author: up to now, the new coronal pneumonia virus (sars-cov-2) has caused more than 70000 confirmed cases in China
In view of the high similarity between sars-cov-2
-
Novel coronavirus pneumonia: advantages and disadvantages of recognizing antibodies
Time of Update: 2020-02-15
In the aspect of anti-virus, non neutralizing surface antibody combines with virus and mediates the phagocytosis of immune cells, which are mainly macrophages (specialized phagocytes in human body).
-
New crown rehabilitation patients with antibodies! President of Jinyintan hospital implores donation of plasma
Time of Update: 2020-02-14
Author: Gu Lulu said in the evening of February 13 that Sinopharm China biology had completed the collection of plasma from some convalescent patients, and carried out
-
Nat biotechnol: capture of uncultured bacteria with specific antibodies produced by reverse genetics
Time of Update: 2020-02-08
By focusing on bacteria present in the human oral cavity, podar and his team compared available sequence data from uncultured microorganisms with previously cultured bacteria to identify potential cell surface proteins.
-
Nat Med: antibody therapy can enhance T cell immune response in HIV infected people
Time of Update: 2020-02-07
The related research results were published online in the journal Nature Medicine on February 3, 2020, and the title of the paper is "combination anti-HIV-1 antibody therapy is associated with increased virus specific T cell immunity".
-
The latest research reveals a new method of antibody drug targeting damaged heart
Time of Update: 2020-02-07
A study from the University of North Carolina and the University of North Carolina, Chapel Hill, reported a new type of platelet particle that can target anti-inflammatory drugs to the ischemic heart.
-
New drug gma301 of Hongyun Huaning pulmonary hypertension antibody is approved by FDA
Time of Update: 2020-02-05
Recently, gma301, the original monoclonal antibody new drug of Hongyun Huaning biomedical Co., Ltd., has been approved by the US FDA for clinical trials.
